drugset / Trial / NCT03357822
A Real-World Study of Pegylated Interferon In Nucleoside-treated Patients With Chronic Hepatitis B
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The aim of the prospective real-world study is to evaluate whether sequential combination therapy with pegylated interferon plus entecavir/tenofovir could induce higher rates of HBsAg loss in nucleoside-treated patients with chronic hepatitis B compared to continuous nucleoside treatment.
Timeline
- Start
- 2018-01-25
- Primary completion
- 2022-01-25
- Completion
- 2022-07-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2a | Protein / enzyme biologic | 180 ug | Subcutaneous |
| Background | Entecavir | Small molecule | 0.5 mg | Oral |
| Background | Tenofovir disoproxil fumarate | Small molecule | 300 mg | Oral |